MENU

Can Filana Therapeutics (FLNA) Stock Reach $6.50?

a developer of novel drugs

A.I.Advisor
published price charts
A.I.Advisor
Nov 11, 2026

Can Filana Therapeutics (FLNA) Stock Reach $6.50?

Key Takeaways

  • The central target is $6.50, the arithmetic mean of two current analyst price targets—$5.00 and $8.00—both rated Buy.
  • At a recent close near $0.48, reaching $6.50 would require an advance of roughly 1,250%, an extraordinarily large move.
  • The analyst range of $5.00 to $8.00 is unusually wide, reflecting deep uncertainty around a pre-revenue, clinical-stage biotech.
  • The strongest support is the balance sheet: about $47 million in cash (roughly $0.97 per share) against a share price well below that figure, plus a strategic pivot toward TSC-associated epilepsy.
  • The biggest risk is that shares have fallen more than 80% over the past year and the two analyst targets may not fully reflect that collapse.
  • For additional detail on this ticker, explore the Major News and Today's Price Move pages, the Forecast page, and the Earnings page.
  • Explore Trending AI Robots for AI-driven market ideas and trade signals.

Analyst Price Targets and Consensus View

Filana Therapeutics, Inc. (FLNA), formerly known as Cassava Sciences, is a clinical-stage biotechnology company developing simufilam, a filamin A modulator, with a lead indication now focused on tuberous sclerosis complex (TSC)-associated epilepsy, a rare orphan condition. Two current, attributable analyst price targets were reviewed. Maxim Group analyst Jason McCarthy resumed coverage with a Buy rating and a $5.00 target in May 2026 and maintained it in late September 2026. Lucid Capital initiated with a Buy and an $8.00 target in October 2025 and maintained it in September 2026.

The arithmetic mean of these two targets is $6.50, which serves as the central target used here. The low-to-high range of $5.00 to $8.00 is wide—a 60% spread between just two estimates—highlighting how little visibility Wall Street has into a company with no reported revenue. Both firms frame the name around its net cash position and its refocused epilepsy pipeline rather than near-term earnings, and neither target should be read as a guarantee of future price.

Current Market Position and Path Toward the Target

Shares recently traded near $0.48, giving a market capitalization of roughly $23 million. Reaching $6.50 would require a move of approximately 1,250%, a very large advance by any measure. For context, the 52-week range is roughly $0.43 to $3.45, meaning the central target sits well above even the stock's 52-week high. Notably, the company holds about $47 million in cash with no debt, equivalent to roughly $0.97 per share—more than double the current share price. Shares trading below cash backing typically signal that the market places little value on the clinical pipeline, which also frames the gap between the price and the analyst targets.

What Could Support a Move Toward the Target

The most concrete support is financial rather than clinical. With net cash of roughly $0.97 per share versus a price near $0.48, the stock trades at a steep discount to its liquidation value, a setup that can attract value-oriented and event-driven investors. Strategically, the company has rebranded and pivoted simufilam toward TSC-associated epilepsy, an orphan indication with significant unmet need and limited competition; positive clinical data in that setting could force a re-rating of a name the market has largely written off. Analyst revisions would be a key catalyst, as even a modestly higher target from the current two-analyst set would lift the calculated mean.

What Could Prevent the Target From Being Reached

The risks are substantial. The company is pre-revenue, reported EPS (earnings per share) of about negative $0.87 over the trailing twelve months, and is burning cash, so future equity raises could dilute shareholders further. The move away from Alzheimer's disease reflects a pipeline setback that damaged investor confidence, and with only two covering analysts, the existing targets may not have been recalibrated to the latest share-price collapse. Short interest near 12% of shares outstanding adds a layer of volatility, and the company has a history of reverse splits—a signal of prolonged capital stress.

Technical Levels and Market Structure

The shares sit near the bottom of their 52-week range, with the $0.43 area marking a notable support zone just below recent prices. Shares trade well beneath their 50-day and 200-day moving averages—roughly $0.74 and $1.30, respectively—confirming a firmly entrenched downtrend. On any recovery, those moving averages and the former trading levels between roughly $0.70 and $1.00 would present successive resistance zones, far before the $6.50 central target becomes relevant.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, though for a pre-revenue biotech the effective catalyst timeline can differ materially. Investors should monitor cash runway and any financing activity, progress and data readouts from the TSC-associated epilepsy program, changes to the small analyst target set, and the pace of cash burn reported each quarter. Dilution, reverse-split risk, and clinical updates are likely to matter far more to the share price than broader market conditions.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals as market conditions, technical behavior, and AI-driven analysis evolve. Traders can use the tool to discover new opportunities, keep an eye on existing positions, and spot changing trends more efficiently than manual scanning allows. For a volatile, news-driven name like FLNA, automated signal monitoring can help investors stay current without watching every tick.

Final Assessment

The $6.50 central target is the mean of just two analyst price targets—$5.00 from Maxim Group and $8.00 from Lucid Capital—and implies a move of roughly 1,250% from a price near $0.48. That is an enormous gap, and the wide range between the two estimates underscores genuine disagreement and uncertainty. The clearest support is the balance sheet, with net cash far above the share price and a refocused orphan-disease strategy, while the clearest obstacles are the absence of revenue, ongoing cash burn, dilution risk, and a pipeline that the market currently discounts heavily. Investors should watch cash runway, TSC-related clinical updates, and any analyst revisions rather than treating the target as a forecast. No outcome is assured.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

FLNA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, FLNA has been loosely correlated with ALT. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if FLNA jumps, then ALT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FLNA
1D Price
Change %
FLNA100%
+14.52%
ALT - FLNA
41%
Loosely correlated
-5.67%
SANA - FLNA
41%
Loosely correlated
-8.62%
DMAC - FLNA
40%
Loosely correlated
+2.87%
JAGX - FLNA
40%
Loosely correlated
-30.58%
BEAM - FLNA
38%
Loosely correlated
-0.19%
More
Can Filana Therapeutics (FLNA) Stock Reach $6.50?